When your weight plateaus on a GLP1 drug Plateaus in weight loss are normal, even on GLP1 drug therapy
It supports the natural metabolic pathway the body already uses to turn fat into usable energy
The exact pathophysiology involves increased intraluminal pressure, weakening of the colonic wall, and alterations in gut microbiota, though the precise mechanisms remain under investigation
Current evidence suggests dulaglutide (Trulicity) and extended-release exenatide (Bydureon) generally demonstrate lower nausea rates (approximately 8-12% at lower doses) compared to twice-daily exenatide or higher-dose semaglutide and liraglutide used for weight management
This could include appetite suppressants, B12 injections, Lipotropic injections, or a combination of methods
Testing MTHFR and other relevant genetic markers can identify these individuals, though routine genetic testing for b12 supplementation decisions remains controversial